| Written | 2015-09 | Christine Bellanné-Chantelot, Isabelle Plo |
| Département de Génétique, Hôpitaux Universitaires Pitié-Salpétrière-Charles Foix, Paris (CBC); INSERM UMR1170, Institut Gustave Roussy, Villejuif (CBC, IP), France christine.bellanne-chantelot@aphp.fr; isabelle.plo@gustaveroussy.fr |
| Abstract | Review on Familial Myeloproliferative Disorders, with data on clinics, and the genes involved. |
| Keyword | Familial; Myeloproliferative disorders; Hereditary erythrocytosis; Hereditary thrombocytosis; TERT; GSKIP; ATG2B; RBBP6 |
| Identity |
| Other names | Familial myeloproliferative neoplasms |
| Hereditary erythrocytosis | |
| Hereditary thrombocytosis | |
| Atlas_Id | 10180 |
| Genes implicated in | TERT GSKIP ATG2B RBBP6 BML BRCA2 BRIP1 CEBPA ELANE FANCA FANCB FANCC FANCD2 FANCE FANCF FANCG FANCI FANCL FANCM HAX1 PALB2 RAD51C RUNX1 SLX4 WAS |
| Note | Myeloproliferative neoplasms (MPN) are clonal and chronic hematological malignancies caused by genetic defects that result in overproduction of one or several myeloid lineages (erythroïd, megakaryocytic and granulocytic lineages). The classic MPN or Ph-chromosome-negative MPN include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). Familial MPN are estimated to 2 to 10% according to studies. They are divided in two overlapping entities: - True MPN disorders with germline predisposition that are familial clustering of MPN with autosomal dominant inheritance and incomplete penetrance. These familial cases are indistinguishable from the sporadic cases of MPN in terms of clinical features and acquired genetic abnormalities. - Hereditary MPN-like disorders with clinical symptoms of MPN but affecting a single lineage involvement. They include hereditary thrombocytosis ( THPO, MPL, JAK2 genes), hereditary erythrocytosis ( EPOR, VHL, EGLN1 and EPAS1 genes) and hereditary neutrophilia ( |
| Inheritance | Most of familial MPN are compatible with an autosomal dominant with incomplete penetrance. However, an autosomal recessive pattern has been suggested by some authors and could not be excluded. |
| Clinics |
| Phenotype and clinics | Familial MPN include the three classic MPN or Ph-chromosome-negative MPN: PV, ET, and PMF. Patients with familial MPN have the same clinical presentation at diagnosis as patients with sporadic MPN. They develop the same type of complications (thrombosis and hemorrhage) and disease evolution (post-PV myelofibrosis, post-ET myelofibrosis, and acute myeloid leukemia). The distribution of MPN phenotypes within MPN families is homogeneous in half of cases (all affected family cases have the same MPN). |
| Neoplastic risk | RISK increased of transformation to acute myeloid leukemia (AML) |
| Treatment | The recommendations are those used for sporadic MPNS. In low-risk patients, phlebotomy in PV patients and low-dose aspirin in ET patients are recommended. In the presence of risk factors for thrombosis, hydroxyurea is used as first-line treatment and busulfan or interferon-α as second-line. Novel therapies based on JAK2 inhibitors have been developed and up to date, are restricted to patients with myelofibrosis. |
| Evolution | The main cause of death is the evolution to myelofibrosis and AML. In familial cases, the incidence annual rate of AML has been estimated to 1.25% patients/year for PV and 0.68% patients/year for ET. |
| Prognosis | Familial PV: 83% of overall survival at 10 years; Familial ET: 84% to 100% of overall survival at 10 years; Familial PMF: 30% of overall survival at 10 years. |
| Cytogenetics |
| Cytogenetics of cancer | Chromosomal aberrations observed in familial MPN are similar to those reported in sporadic cases. About two-third of MPN harbor at least one chromosomal aberration. Some of them are more specifically acquired with disease progression to secondary myelofibrosis such as uniparental disomy (UPD) of 9p, gain of 1q whereas others are more frequently associated with post-MPN acute myeloid leukemia such as gain of 1q, deletions of 7q, 5q, 6p, 7p, 3q and UPD of 19q and 22q. |
| Other findings |
| Note | MPNs are driven by at least one somatic acquired mutation (V617F in JAK2 or mutations in MPL and CALR for ET and PMF) and mutations in epigenetic regulators such as TET2, IDH1, IDH2 and Several predisposing single-nucleotide polymorphism (SNP) such as the JAK2 haplotype 46/1 (also named GGCC) in JAK2, SNP rs2736100 in TERT, SNP rs2201862 in MECOM and SNP rs9376092 in HBS1L / MYB have been shown to play a role in the development of MPN in the general population by favoring the acquisition of driver mutations. However, except TERT (detailed below, none of them explain the familial clustering of MPN. |
| Genes involved and Proteins |
| Gene Name | RBBP6 (RB binding protein 6, ubiquitin ligase) |
| Location | 16p12.1 |
| DNA/RNA | |
| Transcription | NM_006910.4 encodes the longest transcript. |
| Protein | |
| Description | Protein of 1792 amino acids. |
| Function | Possible link to P53 function. |
| Mutations | |
| Germinal | All mutations located in the putative p53-binding region. |
| Gene Name | ATG2B (Autophagy-related 2B) |
| Location | 14q32.2 |
| Note | Cooperates with GSKIP, also located in 14q32.2 and included in the 700 kb duplication NC_000014.9:g.95696766_96390792dup (on Assembly GRCh38). |
| DNA/RNA | |
| Transcription | Unique transcript NM_018036. |
| Protein | |
| Description | Protein of 2078 amino acids. |
| Expression | Expressed in CD34+ hematopoietic progenitors and during erythroïd and megakaryocyte differentiation. |
| Function | Overexpression of ATG2B enhances hematopoietic progenitor differentiation, particularly in megacaryocytes and cooperates with classical driver mutations. |
| Mutations | |
| Note | Founder defect in families originated from West-Indies. |
| Germinal | Head-to-tail 700 kb tandem duplication (g.95696766_96390792dup). |
| Somatic | Associated with classical driver mutations such as V617F in JAK2, W515L in MPL and 1099_1050del52 in CALR and with an increased frequency of mutations in TET2, IDH1 and IDH2. |
| Gene Name | GSKIP (GSK3-beta interaction protein) |
| Alias | C14orf129 |
| Location | 14q32.2 |
| Note | Cooperates with ATG2B, also located in 14q32.2 and included in the 700 kb duplication NC_000014.9:g.95696766_96390792dup (on Assembly GRCh38). |
| DNA/RNA | |
| Transcription | NM_001271904 encodes the longest transcript; 3 other transcripts encode the same protein with differences in the 5'UTR. |
| Protein | |
| Description | Protein of 139 amino acids. |
| Expression | in CD34+ hematopoietic progenitors and during erythroïd and megakaryocyte differentiation. |
| Function | Overexpression of GSKIP enhances hematopoietic progenitor differentiation, particularly of megacaryocytes and cooperates with classical driver mutations. |
| Mutations | |
| Note | Founder defect in families originated from West-Indies. |
| Germinal | Head-to-tail 700 kb tandem duplication (g.95696766_96390792dup). |
| Somatic | Associated with classical driver mutations such as V617F in JAK2, W515L in MPL and 1099_1050del52 in CALR and with an increased frequency of mutations in TET2, IDH1 and IDH2. |
| Gene Name | TERT (telomerase reverse transcriptase) |
| Location | 5p15.33 |
| DNA/RNA | |
| Transcription | NM_198253.2 encodes the longest isoform (1); a shorter isoform lacking an alternate in-frame exon in the middle portion of the coding exon is also reported. |
| Protein | |
| Description | Protein of 1132 amino acids. |
| Expression | Blood cells. |
| Function | Telomerase activity, essential for maintaining telomere length. |
| Mutations | |
| Germinal | Allele C of SNP rs2736100, located in the second intron of the TERT gene, is associated with an increased risk for MPN (PV, ET and PMF). |
| To be noted |
| Germline duplication of ATG2B and GSKIP predispose with a high penetrance (above 80%) to several myeloid malignancies, particularly essential thrombocythemia frequently progressing to AML. RBBP6 germline gain-of-function mutations mostly associated with primary myelofibrosis, observed in 5% of the familial and 0.6% of the sporadic MPN cases. TERT rs2736100_C risk allele is significantly associated with familial MPN, whatever the subtype (PV, ET and PMF |
| Bibliography |
| Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders |
| Bellanné-Chantelot C, Chaumarel I, Labopin M, Bellanger F, Barbu V, De Toma C, Delhommeau F, Casadevall N, Vainchenker W, Thomas G, Najman A |
| Blood 2006 Jul 1;108(1):346-52 |
| PMID 16537803 |
| Mutation in TET2 in myeloid cancers |
| Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Massé A, Kosmider O, Le Couedic JP, Robert F, Alberdi A, Lécluse Y, Plo I, Dreyfus FJ, Marzac C, Casadevall N, Lacombe C, Romana SP, Dessen P, Soulier J, Viguié F, Fontenay M, Vainchenker W, Bernard OA |
| N Engl J Med 2009 May 28;360(22):2289-301 |
| PMID 19474426 |
| Role of germline genetic factors in MPN pathogenesis |
| Harutyunyan AS, Kralovics R |
| Hematol Oncol Clin North Am 2012 Oct;26(5):1037-51 |
| PMID 23009936 |
| Germline RBBP6 Mutations In Myeloproliferative Neoplasms. |
| Harutyunyan, AS, Giambruno R, Christian Krendl K, Stukalov A, Klampfl T, Berg T, Milosevic, JD, Chen D, Gisslinger B, Gisslinger H, Rumi E, Passamonti F, Pietra D, Mueller A, Parapatics K, Breitwieser FP, Herrmann R, Colinge J, Bennett KL, Superti-Furga G, Cazzola M, Hammond E and Kralovics R. |
| 55th ASH Annual Meeting and Exposition. Abstract 267. New Orleans, LA, 2013. |
| Common germline variation at the TERT locus contributes to familial clustering of myeloproliferative neoplasms |
| Jäger R, Harutyunyan AS, Rumi E, Pietra D, Berg T, Olcaydu D, Houlston RS, Cazzola M, Kralovics R |
| Am J Hematol 2014 Dec;89(12):1107-10 |
| PMID 25196853 |
| JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms |
| Jones AV, Chase A, Silver RT, Oscier D, Zoi K, Wang YL, Cario H, Pahl HL, Collins A, Reiter A, Grand F, Cross NC |
| Nat Genet 2009 Apr;41(4):446-9 |
| PMID 19287382 |
| Inherited predisposition to myeloproliferative neoplasms |
| Jones AV, Cross NC |
| Ther Adv Hematol 2013 Aug;4(4):237-53 |
| PMID 23926457 |
| Somatic mutations of calreticulin in myeloproliferative neoplasms |
| Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, Them NC, Berg T, Gisslinger B, Pietra D, Chen D, Vladimer GI, Bagienski K, Milanesi C, Casetti IC, Sant'Antonio E, Ferretti V, Elena C, Schischlik F, Cleary C, Six M, Schalling M, Schönegger A, Bock C, Malcovati L, Pascutto C, Superti-Furga G, Cazzola M, Kralovics R |
| N Engl J Med 2013 Dec 19;369(25):2379-90 |
| PMID 24325356 |
| Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression |
| Klampfl T, Harutyunyan A, Berg T, Gisslinger B, Schalling M, Bagienski K, Olcaydu D, Passamonti F, Rumi E, Pietra D, Jäger R, Pieri L, Guglielmelli P, Iacobucci I, Martinelli G, Cazzola M, Vannucchi AM, Gisslinger H, Kralovics R |
| Blood 2011 Jul 7;118(1):167-76 |
| PMID 21531982 |
| Genetic complexity of myeloproliferative neoplasms |
| Kralovics R |
| Leukemia 2008 Oct;22(10):1841-8 |
| PMID 18754034 |
| A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms |
| Olcaydu D, Harutyunyan A, Jäger R, Berg T, Gisslinger B, Pabinger I, Gisslinger H, Kralovics R |
| Nat Genet 2009 Apr;41(4):450-4 |
| PMID 19287385 |
| The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms |
| Olcaydu D, Rumi E, Harutyunyan A, Passamonti F, Pietra D, Pascutto C, Berg T, Jäger R, Hammond E, Cazzola M, Kralovics R |
| Haematologica 2011 Mar;96(3):367-74 |
| PMID 21173100 |
| Myeloproliferative neoplasms: JAK2 signaling pathway as a central target for therapy |
| Pasquier F, Cabagnols X, Secardin L, Plo I, Vainchenker W |
| Clin Lymphoma Myeloma Leuk 2014 Sep;14 Suppl:S23-35 |
| PMID 25486952 |
| CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis |
| Rumi E, Harutyunyan AS, Pietra D, Milosevic JD, Casetti IC, Bellini M, Them NC, Cavalloni C, Ferretti VV, Milanesi C, Berg T, Sant'Antonio E, Boveri E, Pascutto C, Astori C, Kralovics R, Cazzola M; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators |
| Blood 2014 Apr 10;123(15):2416-9 |
| PMID 24553179 |
| Analysis of the ten-eleven translocation 2 (TET2) gene in familial myeloproliferative neoplasms |
| Saint-Martin C, Leroy G, Delhommeau F, Panelatti G, Dupont S, James C, Plo I, Bordessoule D, Chomienne C, Delannoy A, Devidas A, Gardembas-Pain M, Isnard F, Plumelle Y, Bernard O, Vainchenker W, Najman A, Bellanné-Chantelot C; French Group of Familial Myeloproliferative Disorders |
| Blood 2009 Aug 20;114(8):1628-32 |
| PMID 19564637 |
| Germline duplication of ATG2B and GSKIP predisposes to familial myeloid malignancies |
| Saliba J, Saint-Martin C, Di Stefano A, Lenglet G, Marty C, Keren B, Pasquier F, Valle VD, Secardin L, Leroy G, Mahfoudhi E, Grosjean S, Droin N, Diop M, Dessen P, Charrier S, Palazzo A, Merlevede J, Meniane JC, Delaunay-Darivon C, Fuseau P, Isnard F, Casadevall N, Solary E, Debili N, Bernard OA, Raslova H, Najman A, Vainchenker W, Bellanné-Chantelot C, Plo I |
| Nat Genet 2015 Oct;47(10):1131-40 |
| PMID 26280900 |
| New and treatment-relevant risk stratification for thrombosis in essential thrombocythemia and polycythemia vera |
| Tefferi A, Barbui T |
| Am J Hematol 2015 Aug;90(8):683-5 |
| PMID 25872987 |
| New mutations and pathogenesis of myeloproliferative neoplasms |
| Vainchenker W, Delhommeau F, Constantinescu SN, Bernard OA |
| Blood 2011 Aug 18;118(7):1723-35 |
| PMID 21653328 |
| Citation |
| This paper should be referenced as such : |
| Christine Bellann-Chantelot, Isabelle Plo |
| Familial Myeloproliferative Disorders |
| Atlas Genet Cytogenet Oncol Haematol. 2016;20(9):502-505. |
| Free journal version : [ pdf ] [ DOI ] |
| On line version : http://AtlasGeneticsOncology.org/Tumors/FamMyeloproliferID10180.html |
| Other genes implicated (Data extracted from papers in the Atlas) [ 4 ] |
| Genes | ATG2B | CALR | IDH2 |
| External links |
| OMIM | 187950 |
| OMIM | 254450 |
| OMIM | 601626 |
| Orphanet | ARRAY(0x96fb7f8) |
| Other database | ClinVar : SCV000224007-4010 |
| REVIEW articles | automatic search in PubMed |
| Last year articles | automatic search in PubMed |
| © Atlas of Genetics and Cytogenetics in Oncology and Haematology | indexed on : Mon May 11 12:27:14 CEST 2020 |
For comments and suggestions or contributions, please contact us